Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06726096Phase 3Enrolling By Invitation

Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

Role: lead

NCT05345522Phase 2Active Not Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Role: lead

NCT05957107Phase 2Completed

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Role: lead

NCT05256719Phase 1Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Role: lead

NCT06021574Phase 1Completed

A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody

Role: collaborator

NCT05232396Phase 1Completed

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Role: lead

All 6 trials loaded